RxDoctor Payments Data

Louis Barfield, MD

Colon & Rectal Surgery · Baton Rouge, LANPI 1508807819

Payments from drug & device makers

What this record shows

This record is dominated by education: $11,500 of the $17,334 with a category attached, or 66.3%. Intuitive Surgical accounts for 88.5% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $12,665, more than ten times the $308 reported in 2019.

$17,334in general payments, 2019–2025

Across 110 payments — averaging $157.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$15K
  • Kerecis Limited$351
  • Takeda Pharmaceuticals U.S.A., Inc.$199
  • Pacira Pharmaceuticals Incorporated$168
  • Dilon Technologies, Inc.$146
  • Braintree Laboratories, Inc.$136
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$3,55621%
  • Food & beverage$2,27813%
  • Education$11,50066%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,334 in reported general payments places this provider in the 80th percentile of 39 colon & rectal surgery providers in Louisiana.

See all colon & rectal surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$68,615
Medicare patients
153
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulancePlecanatide13$8,412
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates74$4,959
Hydrocortisone27$380
Procto-Med HcHydrocortisone17$313
Neomycin Sulfate45$306
Sodium Chloride0.9 % Sodium Chloride16$136
Metronidazole53$133
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$115
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$75
Gabapentin11$48
Tramadol Hcl11$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$115$8,41213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 39 colon & rectal surgery providers in Louisiana.

Other colon & rectal surgery in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →